All In Biotech

Drug Trial Radar · NCT05866029

Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture

Efficacy of Sequential Denosumab After Teriparatide for 6 Months Compared With Denosumab Monotherapy in Reducing Risk of Osteoporotic Fractures in Patients With New Fractures: a Multicenter Randomized Controlled Trial (STAND Study)

Last checked: Nov 20, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,478 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,478

Planned (sponsor's estimate)

Start

May 26, 2023

Primary completion

Sep 30, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
Peking Union Medical College HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This project anchors osteoporotic fractures, conduct registration and follow-up studies, and conduct prospective treatment studies. By registering for follow-up studies on osteoporotic fractures, it is planned to obtain epidemiological data through registration and follow-up studies; A prospective treatment study for patients with osteoporotic fractures is planned to explore effective treatment strategies through randomized controlled trials; To study biomarkers for osteoporotic refractures, we plan to establish a biomarker warning model through multi omics research; To study imaging biomarkers for osteoporotic refractures, a new imaging technology is proposed to establish an imaging omics warning model.

Conditions

  • Osteoporotic Fractures

Interventions

  • DenosumabDrug

    Active Comparator: 60mg of Denosumab treatment by subcutaneous injection

  • TeriparatideDrug

    Teriparatide was sequentially treated with Denosumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The main study:The incidence of new vertebral fracturesTime frame: Within 24 months of treatment
  2. The sub study:The rate of change in BMD from baseline at lumbar spine in 24 monthsTime frame: Within 24 months of treatment

Locations

58 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Beijing Hospital

    Beijing, China · Recruiting

  • Beijing Pinggu Hospital

    Beijing, China · Recruiting

  • Beijing Shijingshan Hospital

    Beijing, China · Recruiting

  • Beijing Yanhua Hospital

    Beijing, China · Recruiting

  • Peking Union Medical College Hospital

    Beijing, China · Recruiting

  • Peking University Third Hospital

    Beijing, China · Recruiting

  • Jilin Province FAW General Hospital

    Changchun, China · Recruiting

  • The Second XIANGYA Hospital of Central South University

    Changsha, China · Recruiting

  • Changzhou NO.2 People's Hospital

    Changzhou, China · Recruiting

  • The First People's Hospital of Changzhou

    Changzhou, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, China · Recruiting

  • West China Fourth Hospital of Sichuan University

    Chengdu, China · Recruiting

  • The Second People's Hospital of Dalian

    Dalian, China · Recruiting

  • Shengli Oilfield Central Hospital

    Dongying, China · Recruiting

  • Affiliated Hospital of Guizhou Medical University

    Guiyang, China · Recruiting

  • Zhejiang Provincial People's Hospital Bijie Hospital

    Guizhou, China · Recruiting

  • The Fourth Hospital of Harbin Medical University

    Haerbin, China · Recruiting

  • The Second Hospital of Jilin University

    Haerbin, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, China · Recruiting

  • The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

    Hefei, China · Recruiting

  • Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, China · Recruiting

  • Shandong Provincial Hospital

    Jinan, China · Recruiting

  • The Second Hospital of Shandong University

    Jinan, China · Recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, China · Recruiting

  • Gansu Provincial Hospital

    Lanzhou, China · Recruiting

  • Liaocheng People's Hospital

    Liaocheng, China · Recruiting

  • Jiangxi Provincial People's Hospital

    Nanchang, China · Recruiting

  • Zhongda Hospital Southeast University

    Nanjing, China · Recruiting

  • Ningbo NO.2 Hospital

    Ningbo, China · Recruiting

  • Qingdao Municipal Hospital

    Qingdao, China · Recruiting

  • Changhai Hospital

    Shanghai, China · Recruiting

  • Huadong Hospital Affiliated to Fudan University

    Shanghai, China · Recruiting

  • Shanghai Changzheng Hospital

    Shanghai, China · Recruiting

  • Shanghai General Hospital

    Shanghai, China · Recruiting

  • Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

  • Tongji Hospital of Tongji University

    Shanghai, China · Recruiting

  • Huazhong University of Science and Technology Union Shenzhen Hospital

    Shenzhen, China · Recruiting

  • Shenzhen Shiyan People's Hospital

    Shenzhen, China · Recruiting

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.